Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amneal Pharmaceuticals (AMRX), Immunovant (IMVT) and...

Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma, with a price target of $62.00...

Market Cap	$16.52B	P/E Ratio	10.69
52W High	$54.64	52W Low	$32.21
Div Yield	94.0%	Payout Ratio	44.3%
EPS Growth 3Y	161.6%	52W Position	97.1%
Overall Score	71	Value Score	100
Quality Score	55	Technical Score	60

EPS Current Est	$5.05	EPS Next Est	$5.51
EPS Growth Est	+9.1%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPRX	$53.98	-0.96%	1.14M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPRX	$53.98	-1.0%	1.14M
3
4
5
6

RPRX

RPRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Royalty Pharma plc Data in Excel

Get Royalty Pharma plc Data in Excel